A Silent Epidemic We Can No Longer Ignore
Dementia is often mistaken as a natural part of ageing but what if these symptoms are not just ageing? Behind those forgotten names and misplaced memories may lie something much more serious Alzheimer’s disease.
According to the Alzheimer’s Disease International Report (2024), one new case of dementia is diagnosed every three seconds, and the global count is expected to exceed 150 million by 2050. In India alone, more than 8.8 million people are currently living with dementia, and this number may double by 2035.
The true tragedy lies in the delay of diagnosis, when irreversible brain changes have already taken hold. But with recent advancements in medical science, we now stand at the threshold of a diagnostic revolution.
The Breakthrough: Science That Detects Before It’s Too Late
We are proud to introduce the FDA-approved Alzheimer’s Blood & CSF Biomarker Test at our National Reference Lab, now available in India through our partnership with Agappe Diagnostics, powered by Fujirebio Japan’s Lumipulse G technology a world leader in neurodegenerative diagnostics.
This breakthrough test allows clinicians to detect Alzheimer’s disease earlier, more accurately, and less invasively than ever before giving families and physicians valuable time for care, planning, and treatment.
What Makes This Test Different?
Traditionally, diagnosing Alzheimer’s required PET scans or lumbar punctures (CSF testing) both invasive, expensive, and limited in availability. This innovation changes this: a simple blood test can now identify the earliest biochemical signs of Alzheimer’s, even before symptoms fully develop.
The Science at Work
The test measures two key biomarkers that are closely linked to the development of Alzheimer’s disease:
- β-Amyloid 1-42 – associated with the formation of amyloid plaques in the brain
- Phosphorylated Tau (pTau217) – linked to the formation of neurofibrillary tangles that disrupt brain function
By assessing the pTau217/β-Amyloid 1-42 ratio in plasma (blood) or CSF samples, the test provides a highly accurate indication of amyloid plaque buildup the hallmark of Alzheimer’s pathology.
Key Advantages
- FDA-approved Lumipulse G platform ensuring global clinical reliability
- >90% sensitivity and 97% specificity for detecting amyloid plaques
- Less invasive – requires only a simple blood draw or CSF sample
- Faster turnaround – results available within hours instead of days
- Cost-effective and accessible through Agappe’s MISPA i-series CLEIA platforms
This test bridges the gap between high-end neurodiagnostic technologies and real-world accessibility for Indian clinicians and patients.
Why Early Detection Matters
Until now, diagnosing Alzheimer’s required invasive lumbar punctures or costly PET scans that were often out of reach for many families.
This innovative biomarker test changes that. It provides an accurate, affordable, and accessible solution — helping doctors detect Alzheimer’s much earlier, when interventions can be most effective.
Early diagnosis enables the use of disease-modifying therapies such as lecanemab (Leqembi) and donanemab (Kisunla), both of which show promise in slowing cognitive decline when started at the earliest stage.
Who Should Consider the Test
- Adults aged 50 and above show signs of memory loss or confusion
- Patients under neurology or dementia evaluation
- Individuals with a family history of Alzheimer’s disease
- Participants in clinical or therapeutic research on neurodegenerative disorders
⚠️ Note: The test is not intended for asymptomatic screening and must be interpreted alongside clinical evaluations and imaging.
Clinical & Practical Impact
| Feature | Significance |
| Less Invasive | Requires only blood or CSF; safer and easier for patients |
| Early Detection | Identifies Alzheimer’s pathology before dementia progresses |
| Locally Manufactured | Improves affordability and availability in India |
| Regulatory Approved | Based on FDA-cleared Lumipulse G technology |
| Adjunctive Role | Complements clinical and imaging findings for accurate assessment |
Expert Insight
“As a national reference laboratory, we are committed to bringing world-class diagnostics to India. With Agappe’s Alzheimer’s biomarker assays, we can now detect Alzheimer’s early empowering clinicians and families to take timely action, because every day counts in preserving memory and dignity.”
—Dr. Geetanjali Gupta, Lab Director
Under the supervision of Dr. Ravi Gaur as technical advisor and Dr. Geetanjali’s team of experts Dr. Lalit, Consultant Pathologist and Dr. Pawan, Senior Consultant curated panels Like Dementia Screening, Dementia Dx and Dementia Monitoring were launched.
A Human Perspective: Beyond Science, It’s About Time
Behind every report is a story of a family seeking answers, a caregiver searching for clarity, a loved one struggling to remember.
“Early diagnosis is not just about medicine it’s about memories, relationships, and dignity. Every day gained through early detection is a day more of togetherness.”
Alzheimer’s is a time-related illness as well as a memory disease. And now, time is also finally on our side.
Now Available Across Our National Laboratory Network
We are among the first laboratories in India to offer this FDA-approved Alzheimer’s Blood & CSF Biomarker Test, combining advanced science with compassionate care to help families and clinicians take timely action.
For test booking, clinician partnerships, or referral support:
🔗https://oncquestlabs.com/test/dementiadx-panel
📞Phone: 0124-6650000
Together, let’s detect early, act early, and remember for longer.
